Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Diabetic patients suffer augmented severity of myocardial infarction. Excessive activation of the mammalian target of rapamycin (mTOR) and decreased activation of STAT3 are implicated in diabetic complications. Considering the potent cardioprotective effect of mTOR inhibitor, rapamycin, we hypothesized that reperfusion therapy with rapamycin would reduce infarct size in the diabetic hearts through STAT3 signaling. Hearts from adult male db/db or wild type (WT) C57 mice were isolated and subjected to 30 min of normothermic global ischemia and 60 min of reperfusion in Langendorff mode. Rapamycin (100 nM) was infused at the onset of reperfusion. Myocardial infarct size (IS) was significantly reduced in rapamycin-treated mice (13.3 ± 2.4 %) compared to DMSO vehicle control (35.9 ± 0.9 %) or WT mice (27.7 ± 1.1 %). Rapamycin treatment restored phosphorylation of STAT3 and enhanced AKT phosphorylation (target of mTORC2), but significantly reduced ribosomal protein S6 phosphorylation (target of mTORC1) in the diabetic heart. To determine the cause and effect relationship of STAT3 in cardioprotection, inducible cardiac-specific STAT3-deficient (MCM TG:STAT3flox/flox) and WT mice (MCM TG:STAT3flox/flox) were made diabetic by feeding high fat diet (HFD). Rapamycin given at reperfusion reduced IS in WT mice but not in STAT3-deficient mice following I/R. Moreover, cardiomyocytes isolated from HFD-fed WT mice showed resistance against necrosis (trypan blue staining) and apoptosis (TUNEL assay) when treated with rapamycin during reoxygenation following simulated ischemia. Such protection was absent in cardiomyocytes from HFD-fed STAT3-deficient mice. STAT3 signaling plays critical role in reducing IS and attenuates cardiomyocyte death following reperfusion therapy with rapamycin in diabetic heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yellon, D. M., & Hausenloy, D. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071667 · Cited by 3,797
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199 · cited 1×
“Rapamycin preferentially inhibits mTORC1, although recent studies suggest that prolonged treatment with the drug also inhibits mTORC2 thereby leading to insulin resistance [30, 40].”
BackgroundFunction of Mitochondrial Stat3 in Cellular Respiration
Wegrzyn, J., Potla, R., Chwae, Y.-J., Sepuri, N. B. V., Zhang, Q., Koeck, T., Derecka, M., Szczepanek, K., Szelag, M., Gornicka, A., et al. (2009) · Science · doi:10.1126/science.1164551 · Cited by 1,014 · cited 1×
“Mitochondria from mice with cardiomyocyte-specific deletion of STAT3 displayed reduced activities of complexes I and II of the electron transport chain and decreased oxygen consumption [4, 45].”
BackgroundKhamzina, L., Veilleux, A., Bergeron, S., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0921 · Cited by 562 · cited 1×
“Chronic increase in mTOR activity in T2D causes insulin resistance which contributes to hyperinsulinemia and hyperglycemia [14, 28, 39, 44].”
BackgroundHilfiker-Kleiner, D., Hilfiker, A., Fuchs, M., Kaminski, K., Schaefer, A., Schieffer, B., Hillmer, A., Schmiedl, A., Ding, Z., Podewski, E., et al. (2004) · Circulation Research · doi:10.1161/01.res.0000134921.50377.61 · Cited by 385
Jacoby, J. J., Kalinowski, A., Liu, M.-G., Zhang, S. S.-M., Gao, Q., Chai, G.-X., Ji, L., Iwamoto, Y., Li, E., Schneider, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2134694100 · Cited by 357
Turdi, S., Kandadi, M. R., Zhao, J., Huff, A. F., Du, M., & Ren, J. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.12.007 · Cited by 103
Cited by
New Insights Into the Role of mTOR Signaling in the Cardiovascular System
Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311147 · Cited by 491
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Gourdie, R. G., Dimmeler, S., & Kohl, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.89 · Cited by 332
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Walters, H. E., & Cox, L. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082325 · Cited by 85
Zouein, F. A., Altara, R., Chen, Q., Lesnefsky, E. J., Kurdi, M., & Booz, G. W. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00036 · Cited by 82
Karnewar, S., Vasamsetti, S. B., Gopoju, R., Kanugula, A. K., Ganji, S. K., Prabhakar, S., Rangaraj, N., Tupperwar, N., Kumar, J. M., & Kotamraju, S. (2016) · Scientific Reports · doi:10.1038/srep24108 · Cited by 62
“At the end of the treatments, cells were harvested and re-suspended in 0.4% trypan blue and percent cell viability 41 was counted using countess cell chamber (Life Technologies).”
Influential
Metadata
- Authors
- Das, A., Salloum, F. N., Filippone, S. M., Durrant, D. E., Rokosh, G., Bolli, R., & Kukreja, R. C.
- Venue
- Basic Research in Cardiology
- Published
- 2015-04-25
- Volume
- 110
- Issue
- 3
- Pages
- 31-31
- ISSN
- 0003-9217 (ISSN-L)
- 0300-8428
- 1435-1803
- OpenAlex
- W2073596617
- Cited by
- 68
- References
- 8
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.